Comment
doi: 10.1016/j.stem.2021.01.013.
Clinical Trial for Parkinson's Disease Gets a Green Light in the US
Affiliations
- PMID: 33545076
- DOI: 10.1016/j.stem.2021.01.013
Item in Clipboard
Comment
Clinical Trial for Parkinson's Disease Gets a Green Light in the US
Cell Stem Cell.
.
Free article
Abstract
Cell-based therapy is expected as an alternative treatment for Parkinson's disease. In this issue of Cell Stem Cell, two accompanying papers (Kim et al., 2021; Piao et al., 2021) report the induction of clinically applicable dopaminergic neurons from human embryonic stem cells and the results of pre-clinical study toward a clinical trial.
Copyright © 2021 Elsevier Inc. All rights reserved.
Comment on
-
Preclinical Efficacy and Safety of a Human Embryonic Stem Cell-Derived Midbrain Dopamine Progenitor Product, MSK-DA01.Cell Stem Cell. 2021 Feb 4;28(2):217-229.e7. doi: 10.1016/j.stem.2021.01.004. Cell Stem Cell. 2021. PMID: 33545080 Free PMC article.
-
Biphasic Activation of WNT Signaling Facilitates the Derivation of Midbrain Dopamine Neurons from hESCs for Translational Use.Cell Stem Cell. 2021 Feb 4;28(2):343-355.e5. doi: 10.1016/j.stem.2021.01.005. Cell Stem Cell. 2021. PMID: 33545081 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
